Target intelligence / Profile preview

Iron-responsive element-binding protein 2 (IREB2)

Target
IREB2
Molecular classification
RNA-binding protein, Regulatory protein, Iron-sulfur protein, Post-transcriptional regulator
01

Overview

Iron-responsive element-binding protein 2 (IREB2, also called IRP2) is an RNA-binding regulatory protein that controls cellular iron homeostasis. It binds to iron-responsive elements (IREs), stem-loop structures in the untranslated regions of target mRNAs, such as those coding for ferritin, transferrin receptor, and iron-metabolism-related proteins. By binding to IREs in either the 5' or 3' UTR, IREB2 represses translation (e.g., of ferritin) or stabilizes mRNA (e.g., transferrin receptor), balancing iron uptake, export, and storage in response to cellular iron status. IRP2 is distinct from its paralog IRP1/ACO1 in lacking aconitase activity and is regulated via proteasomal degradation in iron-replete conditions, with the strongest expression in the intestine and brain. Variants and overexpression of IREB2 have been implicated in cancer (especially prostate and lung), some neurodegenerative conditions, and COPD

Other names
IRP2IRBP2IRE-BP2IFR2iron-responsive element binding protein 2
02

Mechanism of action

Drugs altering iron metabolism may indirectly modulate IREB2 activity, but no selective therapeutics directly target IREB2

03

Biological functions

Regulation of iron homeostasismRNA translation repression (binds IREs in 5'UTR)mRNA stabilization (binds IREs in 3'UTR)Iron ion bindingMetabolic process regulation
04

Disease associations

Cancer (notably prostate cancer and associations with lung cancer)Neurodegenerative disease (e.g., early-onset neurodegeneration with anemia)Chronic obstructive pulmonary disease (COPD)Protein-deficiency anemia
05

Safety considerations

Safety concerns are related to iron homeostasis dysregulation: targeting IRP2 could cause unintended changes in cellular iron levels, leading to oxidative stress or anemia
06

Biomarkers

IRP2/IREB2 expression may serve as a biomarker in certain cancers (e.g., prostate cancer) and disorders of iron metabolism

Beyond the preview

Go deeper on Iron-responsive element-binding protein 2 (IREB2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iron-responsive element-binding protein 2 (IREB2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call